Genome-Wide Association and Exon Sequencing Study in IPF
Genome-Wide Association and Exon Sequencing Study in IPF
批准号:
7818299
负责人:
NAFTALI KAMINSKI
金额:
$50.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-08-31
关键词:
AddressAffectAfrican AmericanAreaBioinformaticsBiological MarkersCandidate Disease GeneCaucasiansCaucasoid RaceChicagoClinicalCollaborationsCollectionComplexComputational BiologyCopy Number PolymorphismCoupledCrohn&aposs diseaseDNADNA SequenceDataDatabasesDepositionDevelopmentDiseaseDisease ProgressionEnsureExonsFamilyFrequenciesGenesGeneticGenetic DeterminismGenetic Predisposition to DiseaseGenetic VariationGenomicsGenotypeHamman-Rich syndromeHeartHematological DiseaseImageIndividualInterstitial Lung DiseasesLeadLeadershipLungLung diseasesMutationOutcome MeasurePathogenesisPathway interactionsPatientsPhenotypePopulationPredispositionResearchResourcesRiskSamplingSeveritiesSeverity of illnessSingle Nucleotide PolymorphismSpecialistTechnologyTestingUnited StatesUnited States National Institutes of HealthVariantcohortdatabase of Genotypes and Phenotypesdisease phenotypeeffective therapygenetic variantgenome wide association studymeetingsmortalitynovelnovel strategiesnovel therapeutic interventionoutcome forecastpreventracial and ethnicrepositorysegregationsuccesstelomerase reverse transcriptasetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (08) Genomics and Specific Challenge Topic, 08-HL-101* "Identify causal genetic variants associated with heart, lung, and blood diseases by application of targeted DNA capture and massively parallel sequencing technologies followed by selective genotyping of DNA samples from large well-phenotyped populations". Idiopathic Pulmonary fibrosis (IPF) is a progressive untreatable lung disease. IPF has eluded causal genetic determinants that may provide targets for novel therapeutic approaches. The objective of this proposed research is to identify causal genetic variants contributing to risk of IPF using a Genome-wide association studies (GWAS) panel in a large complied cohort. Each DNA sample is accompanied by detailed phenotypic data. To meet this objective we have the following specific aims: Specific Aim 1. To establish a combined cohort of over 700 IPF patients and perform a Genome Wide Association Study (GWAS) in 450 subjects with IPF. The hypothesis to be tested is that inheritable genetic factors affect individual susceptibility of IPF. To accomplish this we will establish clinically meaningful definitions for disease phenotypes in a merged manually and electronically curated database of all 700 collaborator patient sample sets of IPF patients and then perform a complete a GWAS using Affymetrix SNP 6.0 GeneChip(R) in 450 IPF patients and deposit the GWAS genotype and phenotype data in the NIH repository in dbGap. Specific Aim 2. Conduct both standard and novel analyses in genetic variation by phenotypes severity and rapidity of progression. The hypothesis to be tested is that inheritable genetic factors influence prognosis and severity of the disease. To accomplish this we will determine SNPs associated with IPF utilizing publicly deposited genotyped control GWAS data and evaluate copy number polymorphisms via available probes, and test for association with IPF phenotypes and determine if the associated variants differ in frequency between subjects with "rapidly progressive" IPF with high mortality versus those with "slow" IPF, severity grade or other clinical outcome measures Specific Aim 3. Perform Exon-Wide targeted DNA sequencing and genotyping to validate the GWAS associated genetic variants and to discover functional variations in Caucasians and African Americans with IPF. The hypothesis to be tested is that Exon-Wide sequencing of subjects with different ethnic and racial backgrounds and severity cohorts will allow the identification of causal/functional variants associated with IPF. We will replicate the most significant associations with a selective SNP array in a replicate IPF patient cohort of 200 subjects and then perform Exon-wide sequencing of 48 genes in 160 Caucasian and African American subjects using Illumina 454 technology and conduct a statistical analysis of exon variants discovered in sub- aim b. We expect that completion of a genome-wide association study using clinically meaningful phenotypes coupled to exon-wide re-sequencing will lead to identification of the genes and the specific genetic variants that contribute to the development of IPF. This can then be used as guide to lead to new approaches for preventing and treating this deadly disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrating single-cell based transcriptomic signatures for identifying therapeutic targets of COPD
-
批准号:10360807
-
项目类别:
-
资助金额:$12.56万
-
财政年份:2022
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Integrating single-cell based transcriptomic signatures for identifying therapeutic targets of COPD
-
批准号:10540331
-
项目类别:
-
资助金额:$12.56万
-
财政年份:2022
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Normal Aging Lung Cell Atlas (NALCA)
-
批准号:10321584
-
项目类别:
-
资助金额:$62.61万
-
财政年份:2019
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Normal Aging Lung Cell Atlas (NALCA)
-
批准号:10275008
-
项目类别:
-
资助金额:$8.6万
-
财政年份:2019
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Normal Aging Lung Cell Atlas (NALCA)
-
批准号:10546679
-
项目类别:
-
资助金额:$8.6万
-
财政年份:2019
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Normal Aging Lung Cell Atlas (NALCA)
-
批准号:10094238
-
项目类别:
-
资助金额:$64.18万
-
财政年份:2019
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis
-
批准号:10307633
-
项目类别:
-
资助金额:$78.81万
-
财政年份:2018
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis
-
批准号:10063549
-
项目类别:
-
资助金额:$87.99万
-
财政年份:2018
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Mir-29 mimicry as a therapy for pulmonary fibrosis
-
批准号:8931051
-
项目类别:
-
资助金额:$127.86万
-
财政年份:2014
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Mir-29 mimicry as a therapy for pulmonary fibrosis
-
批准号:9144911
-
项目类别:
-
资助金额:$143.45万
-
财政年份:2014
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Mir-29 mimicry as a therapy for pulmonary fibrosis
-
批准号:8758509
-
项目类别:
-
资助金额:$143.17万
-
财政年份:2014
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Mir-29 mimicry as a therapy for pulmonary fibrosis
-
批准号:9534175
-
项目类别:
-
资助金额:$138.79万
-
财政年份:2014
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Surrogate Biomarkers for Disease Progression in IPF
-
批准号:7911854
-
项目类别:
-
资助金额:$50.19万
-
财政年份:2009
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Genome-Wide Association and Exon Sequencing Study in IPF
-
批准号:7935442
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Molecular Phenotypes within and across disease boundaries in IPF and COPD
-
批准号:7822479
-
项目类别:
-
资助金额:$1.83万
-
财政年份:2009
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Molecular Phenotypes within and across disease boundaries in IPF and COPD
-
批准号:7691778
-
项目类别:
-
资助金额:$73.8万
-
财政年份:2008
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Molecular Phenotypes within and across disease boundaries in IPF and COPD
-
批准号:8119721
-
项目类别:
-
资助金额:$71.14万
-
财政年份:2008
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Molecular Phenotypes within and across disease boundaries in IPF and COPD
-
批准号:7904863
-
项目类别:
-
资助金额:$71.9万
-
财政年份:2008
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Surrogate Biomarkers for Disease Progression in IPF
-
批准号:7524106
-
项目类别:
-
资助金额:$69.37万
-
财政年份:2007
-
负责人:NAFTALI KAMINSKI
-
依托单位:
Surrogate Biomarkers for Disease Progression in IPF
-
批准号:7231799
-
项目类别:
-
资助金额:$55.57万
-
财政年份:2006
-
负责人:NAFTALI KAMINSKI
-
依托单位:
海外基金